Select Language
FOLR1
FOLR1 Overview
| English Name | Folate receptor alpha | Approved Drugs | 3 |
| Drugs in Clinical Trials | 27 | Target Synonym | FRalpha，KB cells FBP，Adult folate-binding protein，Folate receptor 1，Folate receptor alpha，FR-alpha，FOLR1，Ovarian Tumor-Associated Antigen MOv18，Folate Receptor 1 (Adult)，Folate Receptor， Adult，FOLR，FBP，Folate Binding Protein，FRα |
| Highest Development Stage | Approved | ||
| English Name | Folate receptor alpha |
| Target Synonym | FRalpha，KB cells FBP，Adult folate-binding protein，Folate receptor 1，Folate receptor alpha，FR-alpha，FOLR1，Ovarian Tumor-Associated Antigen MOv18，Folate Receptor 1 (Adult)，Folate Receptor， Adult，FOLR，FBP，Folate Binding Protein，FRα |
| Approved Drugs | 3 |
| Drugs in Clinical Trials | 27 |
| Highest Development Stage | Approved |
FOLR1 Product List
- Product Category
Protein (22)Cell (1)Antibody (1)
- Product Status
Launched (24)
- Species
Mouse (6)Cynomolgus / Rhesus macaque (4)Human (13)Rabbit (1)
- Tag
His Tag (10)His Tag & Avi Tag (6)Fc Tag (4)Fc Tag & Avi Tag (2)- (2)
- Conjugate
Unconjugated (11)Biotin-labeled (8)FITC Labeled (1)PE Labeled (2)APC Labeled (1)- (1)
Total: 24
- 1
- 2
- 3
FOLR1 Background
Folate Receptor 1 (FOLR1) is also known as Folate receptor alpha, Folate Binding Protein (FBP), FOLR, and is a member of the folate receptor (FOLR) family. Members of this gene family have a high affinity for folic acid and for several reduced folic acid derivatives, and mediate delivery of 5-methyltetrahydrofolate to the interior of cells. Mature FOLR1 is an N-glycosylated protein that is anchored to the cell surface by a GPI linkage. FOLR1 is predominantly expressed on epithelial cells and is dramatically upregulated on many carcinomas. FOLR1 is internalized to the endosomal system where it dissociates from its ligand before recycling to the cell surface. A soluble form of FOLR1 can be proteolytically shed from the cell surface into the serum and breast milk. Defects in FOLR1 are the cause of neurodegeneration due to cerebral folate transport deficiency (NCFTD). NCFTD is an autosomal recessive disorder resulting from brain-specific folate deficiency early in life.
FOLR1 Synonyms
FOLR-1,FBP,FOLR,FRα
Antibody Project Trading Platform
| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| FRα BsAb - 01 | PCC | Bispecific | Humanized Mouse,Nanobody | Solid Tumor | Ovarian cancer,Non-small cell lung cancer |
Project Cooperation
| Project Name | Drug Type | Therapeutic Area | Indication | Stage | Rights Area |
|---|---|---|---|---|---|
| FRα BsAb-ADC | Bispecific antibody | Oncology/Cancer | Ovarian cancer | Preclinical | Global |
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Ricorfotide vedotin | CBP-1008 | Phase 3 Clinical | Coherent Biopharma Suzhou Co Ltd | Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours | Details |
| Arfolitixorin | ISO-901; 6R-MTHF | Phase 3 Clinical | Isofol Medical Ab | Colonic Neoplasms; Colorectal Neoplasms; Osteosarcoma; Rectal Neoplasms | Details |
| Rinatabart Sesutecan | GEN1184; GEN-1184; PRO-1184 | Phase 3 Clinical | ProfoundBio (Suzhou) Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Mesothelioma; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Uterine Neoplasms | Details |
| Sofetabart Mipitecan | LY4170156; LY-4170156 | Phase 3 Clinical | Eli Lilly And Company, Loxo Oncology Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Neoplasm Metastasis; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| Torvutatug Samrotecan | AZD5335; AZD-5335 | Phase 3 Clinical | Astrazeneca Plc | Adenocarcinoma of Lung; Carcinoma, Ovarian Epithelial; Endometrial Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Diseases; Solid tumours | Details |
| BAT-8006 | BAT8006; BAT-8006 | Phase 3 Clinical | Bio-Thera Solutions Ltd | Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours | Details |
| Luveltamab tazevibulin | STRO-002 | Phase 2 Clinical | Sutro Biopharma Inc | Carcinoma, Endometrioid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Endometrial Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours | Details |
| EB-NK-FM (FRalpha/MUC16) | EB-NK-FM | Phase 2 Clinical | Beijing Biotech | Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Peritoneal Neoplasms | Details |
| EB-NK-MF (MSLN/FRalpha) | EB-NK-MF | Phase 2 Clinical | Beijing Biotech | Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Glioblastoma; Glioma; Peritoneal Neoplasms | Details |
| 18F-AzaFol | AzaFol; 18F-AzaFol; [18F]-AzaFol | Phase 2 Clinical | Insel Gruppe AG, University Hospital Bern | Giant Cell Arteritis; Lung Neoplasms; Neoplasms; Ovarian Neoplasms | Details |
| Farletuzumab ecteribulin | MORAb-202 | Phase 2 Clinical | Bristol-Myers Squibb Company, Eisai Co Ltd, Morphotek Inc | Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Solid tumours | Details |
| 4S-CAR-FRa | 4S-CAR-FRa | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Carcinoma, Transitional Cell; Urinary Bladder Neoplasms | Details |
| CBP-1019 | CBP-1019 | Phase 2 Clinical | Coherent Biopharma Suzhou Co Ltd | Breast Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Gastrointestinal Neoplasms; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Thoracic Neoplasms; Urogenital Neoplasms | Details |
| Noscapine-folate conjugate | Phase 1 Clinical | Emory University | Hematologic Neoplasms; Inflammation | Details | |
| MOv-18 IgE | MOv-18 IgE; MOv18; MOv-18 | Phase 1 Clinical | Cancer Research UK, King'S College London | Neoplasms; Ovarian Neoplasms | Details |
| MOv19-BBz CAR-T cells Therapy | Phase 1 Clinical | University Of Pennsylvania | Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms | Details | |
| ITIL-306 | ITIL-306 | Phase 1 Clinical | Instil Bio Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Genital Neoplasms, Female; Solid tumours | Details |
| IMGN-151 | IMGN-151 | Phase 1 Clinical | Immunogen Inc | Breast Neoplasms; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Ovarian Neoplasms; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Details |
| GenSci-140 | GenSci140; GenSci-140 | Phase 1 Clinical | Changchun GeneScience Pharmaceuticals Co Ltd | Ovarian Neoplasms; Solid tumours | Details |
| IBI-3010 | IBI-3010; IBI3010 | Phase 1 Clinical | Neoplasm Metastasis; Solid tumours | Details | |
| SYS-6041 | SYS6041; SYS-6041 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Neoplasms; Solid tumours | Details |
| FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy(Fred Hutchinson Cancer Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Leukemia, Myeloid, Acute; Osteosarcoma | Details | |
| [177Lu]Lu-EVS459 | GIZ943; GIZ-943; [177Lu]Lu-EVS459; EVS-459 | Phase 1 Clinical | Novartis Pharma Ag | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Ovarian Neoplasms | Details |
| ZW-191 | ZW-191 | Phase 1 Clinical | Zymeworks Inc | Carcinoma, Non-Small-Cell Lung; Genital Neoplasms, Female; Ovarian Neoplasms; Solid tumours | Details |
| AMT-151 | AMT-151 | Phase 1 Clinical | Multitude Therapeutics Inc | Adenocarcinoma of Lung; Adenocarcinoma, Clear Cell; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Fallopian Tube Neoplasms; Mesothelioma; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| UB-TT170 | UB-TT-170; UB_TT170; UB_TT-170; UB-TT170 | Phase 1 Clinical | Umoja BioPharma Inc | Osteosarcoma | Details |
| CBP-1018 | CBP-1018 | Phase 1 Clinical | Coherent Biopharma Suzhou Co Ltd | Carcinoma, Renal Cell; Lung Neoplasms; Prostatic Neoplasms; Solid tumours | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Pafolacianine Sodium | Pteroyl-L-Tyr-S0456; OTL-38; EC-17; OTL-0038 | Approved | On Target Laboratories Inc | Cytalux | United States | Ovarian Neoplasms | On Target Laboratories Inc | 2021-11-29 | Arthritis, Rheumatoid; Breast Neoplasms; Esophageal Neoplasms; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Inflammatory Bowel Diseases; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Pituitary Neoplasms | Details |
| Mirvetuximab soravtansine | M9346-Asulfo-SPDB-DM4; IMGN-853; M9346A-sSPDB-DM4; TAK-853; HDM2002; HDM-2002 | Approved | Immunogen Inc | Elahere, 爱拉赫 | United States | Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Immunogen Inc | 2022-11-14 | Adenocarcinoma, Clear Cell; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinosarcoma; Cystadenoma, Serous; Endometrial Neoplasms; Fallopian Tube Diseases; Fallopian Tube Neoplasms; Neoplasms; Ovarian Neoplasms; Peritoneal Diseases; Peritoneal Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Uterine Neoplasms | Details |
| Folinic Acid | FTHF | Approved | Anemia; Autism Spectrum Disorder; Colorectal Neoplasms; Diarrhea; Down Syndrome; Rectal Neoplasms; Vitamin B 12 Deficiency | Details |
Product Reviews
p***g2025-01-23
0People LikeAs expected, this was a high quality product. I have purchased multiple products from Acro to develop assays in the past. As usual, purity and quantity was confirmed by our in-house quality control group. We are using this in conjunction with #FO1-H82E2 Biotinylated Human FOLR1 Protein, His Avitag. The product was used successfully in an immunization campaign and will also be used for other in-house assays in the future.- D***m2022-10-26 0People LikeWe had to order human folate receptor protein for 100 micrograms unit type for one of our sensitive studies. It was crucial that the product work as intended. We received the product in a timely manner, and the product work as intended for one of our studies. As an employee working at a lab, I thank you for all the scientists working hard to make great products!
D***n2022-10-26 0People LikeWe had previously ordered this product and we made the mistake of ordering the smaller quantity needed. We contacted customer support letting them know that we needed to switch the order to the larger quantity. They were friendly and helpful when resolving this issue. After the switch, the item in question was sent out very quickly and we were able to continue with our study as soon as it arrived.
Load More
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland